Phase 4 N=70 Randomized Quadruple-blind Treatment

Comparison of Pantoprazole and Ranitidine in Dyspepsia

Dyspepsia

Bottom Line

View on ClinicalTrials.gov: NCT01737840 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jul 2015

Primary outcome: Primary: Visual Analogue Scale Score — 39.6; 42.3; 27.6; 28.3 Visual Analogue Scale

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: Pantoprazole (Drug); Ranitidine (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Akdeniz University
Primary completion: Jan 2013

Outcome Measures

Outcome	Result	p-value
PRIMARY Visual Analogue Scale Score	39.6; 42.3; 27.6; 28.3	—
SECONDARY Need for Additional Drug	13; 8	—

Summary

The H0 hypothesis of the study is there is no difference between pantoprazole and ranitidine in treating patients presented with dyspepsia to the emergency department. The H1 hypothesis is there is difference between pantoprazole and ranitidine in treating patients presented with dyspepsia to the emergency department.

Eligibility Criteria

Inclusion Criteria

Epigastric pain
Older than 18 years old

Exclusion Criteria

Diagnosed as cholecystitis, pancreatitis, myocardial infarction, etc.. at the end of the emergency deparment evaluation period.
Pregnancy
Patients with unstable vital signs
Patients used anti-acid, H2 receptor blockers and proton pomp inhibitors in the last one hour.
Allergy to H2 receptor blockers and proton pomp inhibitors.
Patients denied to give inform consent and who are illiterate

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01737840). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.